GOSS vs. AVBP, COGT, RLAY, PAHC, CDMO, SANA, AVDL, TYRA, SEPN, and CRON
Should you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include ArriVent BioPharma (AVBP), Cogent Biosciences (COGT), Relay Therapeutics (RLAY), Phibro Animal Health (PAHC), Avid Bioservices (CDMO), Sana Biotechnology (SANA), Avadel Pharmaceuticals (AVDL), Tyra Biosciences (TYRA), Septerna (SEPN), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry.
Gossamer Bio vs.
ArriVent BioPharma (NASDAQ:AVBP) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, community ranking, profitability, institutional ownership and media sentiment.
In the previous week, ArriVent BioPharma had 2 more articles in the media than Gossamer Bio. MarketBeat recorded 3 mentions for ArriVent BioPharma and 1 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 1.46 beat ArriVent BioPharma's score of 0.91 indicating that Gossamer Bio is being referred to more favorably in the news media.
Gossamer Bio received 135 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 66.23% of users gave Gossamer Bio an outperform vote.
9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 5.0% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
ArriVent BioPharma's return on equity of -43.89% beat Gossamer Bio's return on equity.
ArriVent BioPharma presently has a consensus price target of $36.80, suggesting a potential upside of 50.76%. Gossamer Bio has a consensus price target of $9.20, suggesting a potential upside of 856.44%. Given Gossamer Bio's higher probable upside, analysts clearly believe Gossamer Bio is more favorable than ArriVent BioPharma.
Summary
Gossamer Bio beats ArriVent BioPharma on 6 of the 10 factors compared between the two stocks.
Get Gossamer Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gossamer Bio Competitors List
Related Companies and Tools
This page (NASDAQ:GOSS) was last updated on 1/21/2025 by MarketBeat.com Staff
